Ben Leach

Despite the fact that pazopanib and cabozantinib are not yet approved, researchers are already trying to determine the best way to integrate them into existing treatment regimens.

In early clinical trials, small-molecule inhibitors have demonstrated improvement in response rates in elderly patients with chronic lymphocytic leukemia.

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

A novel assay could determine when patients with metastatic prostate cancer begin to relapse on androgen deprivation therapy, and which patients may respond better to second-line therapies.

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

A phase III study of axitinib as a front-line therapy for metastatic renal cell carcinoma did not meet its primary endpoint of demonstrating a longer median progression-free survival than sorafenib.

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

A secondary analysis of a combination of an investigational hypoxia-targeted agent called TH-302 with gemcitabine slightly improved overall survival, but the results were not statistically significant.

Eli Lilly announced that a combination regimen of their chemotherapy drug Alimta and Avastin failed to improve survival in late stage non-squamous non-small cell lung cancer.

Researchers have identified more than a dozen pathways and factors involving bone disease in patients with multiple myeloma who are at the highest risk of developing complications.

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.

The FDA has approved bosutinib for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant or who have become resistant to prior therapy.

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

On August 16, the US Federal Circuit Court of Appeals ruled 2-1 to uphold its original decision that Myriad Genetics has the right to hold the patent to the BRCA1 and BRCA2 genes.

Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.